secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2021-07-14T23:59:59+00:00
Accession:  0000886163-21-000102
Event type: leadership
Sentiment:  positive
Materiality: 0.45
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand appoints Dr. Jennifer Cochran to board; moves headquarters to Emeryville, CA
--------------------------------------------------------------------------------

- Dr. Jennifer Cochran appointed to board effective July 12, 2021; co-founder of xCella acquired by Ligand in Dec 2020.
- Cochran receives RSUs (1,161 shares) and options (4,508 shares at $126.36) vesting over 3 years plus cash comp.
- Corporate headquarters moved to 5980 Horton Street, Suite 405, Emeryville, CA 94608 effective July 14, 2021; phone unchanged.
- Cochran is Shriram Chair of Bioengineering at Stanford, co-founded Red Tree Venture Capital, and serves on multiple biotech boards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616321000102/0000886163-21-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616321000102/lgnd-20210712.htm
  HTML page:      https://secwatch.observer/filing/0000886163-21-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer